Northland Securities reiterated their sell rating on shares of ResMed Inc. (NYSE:RMD) in a research report sent to investors on Friday morning. Northland Securities currently has a $55.00 price objective on the medical equipment provider’s stock.
Several other analysts also recently commented on the stock. Needham & Company LLC reissued a sell rating on shares of ResMed in a research report on Friday. Zacks Investment Research cut shares of ResMed from a buy rating to a sell rating in a research note on Tuesday, October 24th. Jefferies Group LLC restated a sell rating and issued a $56.00 price objective on shares of ResMed in a research note on Thursday, October 12th. Barclays PLC boosted their price objective on shares of ResMed from $65.00 to $68.00 and gave the stock an underweight rating in a research note on Monday, September 25th. Finally, Credit Suisse Group cut shares of ResMed from an outperform rating to a neutral rating in a research note on Tuesday, August 8th. Five research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $67.29.
ResMed (NYSE:RMD) opened at 84.42 on Friday. The stock has a 50 day moving average of $78.35 and a 200-day moving average of $74.80. The stock has a market cap of $12.01 billion, a P/E ratio of 35.17 and a beta of 0.77. ResMed has a 52 week low of $56.59 and a 52 week high of $87.81.
ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. The company had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 earnings per share. Analysts forecast that ResMed will post $3.06 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/10/30/northland-securities-reaffirms-sell-rating-for-resmed-inc-rmd.html.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.66%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s payout ratio is 56.68%.
In related news, insider David Pendarvis sold 6,364 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $72.10, for a total transaction of $458,844.40. Following the completion of the transaction, the insider now directly owns 84,476 shares in the company, valued at approximately $6,090,719.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $77.56, for a total transaction of $96,950.00. Following the transaction, the chief financial officer now owns 65,941 shares of the company’s stock, valued at $5,114,383.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,232 shares of company stock valued at $8,109,182. Corporate insiders own 1.77% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in ResMed by 6.8% during the 2nd quarter. BlackRock Inc. now owns 14,240,077 shares of the medical equipment provider’s stock valued at $1,108,877,000 after purchasing an additional 904,939 shares during the last quarter. Vanguard Group Inc. raised its stake in ResMed by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 11,914,671 shares of the medical equipment provider’s stock valued at $927,797,000 after purchasing an additional 378,964 shares during the last quarter. FMR LLC raised its stake in ResMed by 38.2% during the 2nd quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after purchasing an additional 1,531,772 shares during the last quarter. Baillie Gifford & Co. raised its stake in ResMed by 0.9% during the 3rd quarter. Baillie Gifford & Co. now owns 4,913,626 shares of the medical equipment provider’s stock valued at $378,154,000 after purchasing an additional 44,340 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in ResMed by 1.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,266,663 shares of the medical equipment provider’s stock valued at $176,505,000 after purchasing an additional 25,925 shares during the last quarter. Hedge funds and other institutional investors own 59.66% of the company’s stock.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
What are top analysts saying about ResMed Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ResMed Inc. and related companies.